Patents Examined by Catherine S Hibbert
  • Patent number: 10266846
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 23, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10266899
    Abstract: The present invention provides novel mitochondrial fusion transcripts and the parent mutated mtDNA molecules that are useful for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: April 23, 2019
    Assignee: MDNA Life Sciences Inc.
    Inventors: Ryan Parr, Brian Reguly, Gabriel Dakubo, Jennifer Creed, Kerry Robinson
  • Patent number: 10258697
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 16, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Zheng-Yi Chen, David Liu, John Anthony Zuris, David B. Thompson
  • Patent number: 10227576
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: March 12, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Stemberg
  • Patent number: 10227596
    Abstract: A translational control method using an RNA-protein interaction motif is provided. The method comprises a step of introducing an mRNA having: a 5?UTR regulation structure comprising: (1) a cap structure at the 5? terminus, (2) a spacer positioned on the 3? side of the cap structure, and (3) one or more RNA motifs positioned on the 3? side of the spacer, which comprises an RNA-protein interaction motif-derived nucleotide sequence or a variant thereof; and a nucleotide sequence encoding a target protein gene on the 3? side of the 5?UTR regulation structure, into a cell in the presence of a protein specifically binding to the RNA motifs, wherein a translational level is decreased as the number of bases of the spacer decreases, and the translational level is decreased as the number of the RNA motifs increases.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 12, 2019
    Assignee: Kyoto University
    Inventors: Hirohide Saito, Kei Endo, Tan Inoue
  • Patent number: 10220102
    Abstract: An isolated nucleic acid sequence encoding the yeast NDI1 protein of SEQ ID NO: 542 or a functional variant thereof is described. The nucleic acid sequence comprises at least 50 codons which are codon optimized compared with the sequence of yeast NDI1 gene of SEQ ID NO: 1.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 5, 2019
    Assignee: THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLD AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN TRINITY COLLEGE DUBLIN
    Inventors: Gwyneth Jane Farrar, Sophia Millington-Ward, Naomi Chadderton, Mathew Alan Carrigan, Paul Kenna
  • Patent number: 10214566
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provide methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Patent number: 10208312
    Abstract: The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcriptional regulation of gene expression using RNA molecules to both repress and activate translation of an open reading frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5? untranslated region (5? UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention designed to operate in prokaryotic cells, the stem of the hairpin secondary structure sequesters the ribosome binding site (RBS). In embodiments of the invention designed to operate in eukaryotic cells, the stem of the hairpin is positioned upstream of the start codon, anywhere within the 5? UTR of an mRNA.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 19, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Farren J. Isaacs, Charles R. Cantor, Daniel J. Dwyer
  • Patent number: 10208350
    Abstract: Methods for assessing infertility and related pathologies and informing treatment type and timing thereof are provided. According to certain embodiments, methods of the invention include determining levels of one or more transcripts present in a sample obtained from a subject suspected of having endometriosis, identifying transcript levels that correspond to a regulation pattern specific to a time-point in a uterine cycle, and characterizing endometriosis of the subject based upon the identified transcript levels. The invention includes methods for assessing age-associated increase in aneuploidy rates based on FSH levels and IVF success rates based on obesity in PCOS patients.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Celmatix Inc.
    Inventors: Piraye Yurttas Beim, David Emlyn Parfitt, Michael Elashoff
  • Patent number: 10201597
    Abstract: The invention relates to methods and materials that can be used to product cytotoxic T cells that target cancer cells expressing the cancer-testis antigen NY ESO-1. Illustrative embodiments of the invention include peripheral blood stem cells transduced with a lentiviral vector that comprises a codon optimized TCR alpha and beta chain polypeptides specific for NY ESO-1. These gene-modified cells are useful, for example, in a hematopoietic stem cell transplantation setting to treat patients diagnosed with NY ESO-1 positive cancers.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Antoni Ribas, Richard C. Koya, Thinle Chodon
  • Patent number: 10196697
    Abstract: A method is provided for characterizing and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: February 5, 2019
    Assignee: ALMAC DIAGNOSTICS LIMITED
    Inventors: Steven Walker, Andrena McCavigan, Timothy Davison, Richard Kennedy, Paul Harkin, Laura Hill
  • Patent number: 10190135
    Abstract: The present disclosure relates to chimeric post-transcriptional regulatory elements (PRE) and vectors useful for expressing a protein in a cell. The PRE contains alpha, beta and optionally gamma subelements selected from different native PRE sequences and are discovered to be more potent than their native counterparts.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: January 29, 2019
    Assignee: Celltheon Corporation
    Inventors: Nikhil Goel, Amita Goel
  • Patent number: 10190124
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 29, 2019
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Patent number: 10174312
    Abstract: The present invention relates to a screening method for a drug target gene by using chemical-genetic profile compendium of the heterozygous deletion fission yeast strain and the comparative genetic analysis using the same. More precisely, the present inventors constructed the chemical-genetic profile compendium for drug candidates from the heterozygous deletion fission yeast strain of Schizosaccharomyces pombe (S. pombe), and then compared with the compendium with the chemical-genetic profile compendium of the budding yeast Saccharomyces cerevisiae (S. cerevisiae) in order to select efficiently drug target genes showing drug sensitivity. The screening method of the present invention can be efficiently used for the identification of a drug target gene in various eukaryotes because it facilitates the selection of a drug target gene showing sensitivity to the drug from the chemical-genetic profile compendium of the heterozygous deletion fission yeast strain.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 8, 2019
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Dong-Uk Kim, Kwang-Lae Hoe
  • Patent number: 10160978
    Abstract: The invention relates to mammalian cells comprising at least one prokaryotic two-component signaling (TCS) pathway comprised of an activator protein A, a response regulator (RR) protein B activated by said protein A, such activation leading to an activated RR protein B, and an output gene C operably linked to a promoter. Transcription from said promoter is activated by activated RR protein B, and the expression of output gene C defines at least a first state (0, no transcription) and a second state (1, detectable transcription). The invention further relates to logic gates designed from such cells, and methods for integrating a plurality of output signals based on the cells and logic gates of the invention.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: December 25, 2018
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Jonathan Hansen, Krishna Kumar Swaminathan
  • Patent number: 10138527
    Abstract: A method for monitoring differentiation into cardiac muscle cells includes keeping, in an alive state, cells into which a reporter gene of luminescent protein configured to vary in luminescence intensity according to an expression of myocardial differentiation marker gene is introduced. The method includes acquiring a luminescence image as a still image by imaging light emitted from the cells in a light shielding state. The method includes acquiring sequential images with illuminating the cells. The method includes associating biological information obtained from the sequential images with biological information obtained from the still image.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 27, 2018
    Assignee: OLYMPUS CORPORATION
    Inventors: Taro Hayashi, Isao Sakane, Yoko Ohashi
  • Patent number: 10132811
    Abstract: The present invention relates to the identification of pancreatic cancer biomarkers for the detection of early pancreatic cancer. The present invention also provides methods of diagnosing pancreatic cancer and distinguishing between pancreatic cancer and chronic pancreatitis. The present invention additionally provides kits that find use in the practice of the methods of the invention.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: November 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lei Zhang, David T. Wong
  • Patent number: 10113183
    Abstract: The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 30, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Janice J. Chou
  • Patent number: 10105422
    Abstract: Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 23, 2018
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Roger Joseph Hajjar, Chang Won Kho, Ah Young Lee
  • Patent number: 10106583
    Abstract: Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 23, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Andre Marozsan, Albert Cupo, John Moore